Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
The DOI matches its Crossref record.
Abstract
OBJECTIVE: This study evaluates the efficacy of agomelatine, the first antidepressant that is an agonist at MT(1)/MT(2) receptors and an antagonist at 5-HT(2C) receptor, in the prevention of relapse of depression following successful response. METHOD: Patients with DSM-IV-TR major depressive disorder who responded to an 8- or 10-week course of agomelatine 25- or 50-mg daily treatment were randomly assigned to receive continuation treatment with agomelatine (n=165) or placebo (n=174) during a 24-week, randomized, double-blind treatment period. The main outcome measure was time to relapse during the double-blind treatment period. The cumulative probability of relapse was calculated using the Kaplan-Meier method of survival analysis. The study was conducted from February 2005 to February 2007. RESULTS: During the 6-month evaluation period, the incidence of relapse was significantly lower in patients who continued treatment than in those switched to placebo (P=.0001). The cumulative relapse rate at 6 months for agomelatine-treated patients was 21.7%; that for placebo-treated patients was 46.6%. Agomelatine was also superior to placebo in preventing relapse in the subset of patients with baseline 17-item Hamilton Depression Rating Scale total score > or = 25. Measures of tolerability and safety of both doses of agomelatine were similar to placebo. No pattern of early relapse or adverse events suggestive of withdrawal symptoms was obtained after abrupt cessation of agomelatine. CONCLUSIONS: The findings are important in 2 respects. First, agomelatine is an effective and safe antidepressant continuation therapy, which confirms efficacy seen in short-term studies. Second, few early relapses were observed in the patient group switched to placebo: the survival curve for placebo separated gradually from that of patients taking agomelatine. We suggest this reflects solely the underlying properties of the illness, which is only possible due to the lack of discontinuation syndrome after agomelatine withdrawal. It underlines the novel clinical profile of agomelatine, which quite likely reflects its innovative pharmacology. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN53193024.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Suicide/suicide attempt is mentioned 19 times (1, 15, 16, 18, 19, 26, 27, 33, 37, 38, 41, 43–46, 48–50, 52)”
From Administrative criteria in the relapse of depressive disorder: a critical appraisal (2026) · cites this paper as [37]
In the citing paper
“Two DBRPCTs on agomelatine had inconsistent results [32, 33].”
From Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis (2023) · cites this paper as [33]
In the citing paper
“In 1980 and 1990s, Dilsaver documented general somatic and gastrointestinal distress; sleep disturbances characterized by initial and middle insomnia or excessively vivid and frightening dreams; akathisia or parkinsonism; hypomania or mania as manifestations of new withdrawal symptoms due to TCA discontinuation [92-95].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [92]
Citations
Cites
Still being checked.
Cited by
Items 101–200 of 341
Melatonin and agomelatine for preventing seasonal affective disorder
Nußbaumer-Streit, B., Greenblatt, A. M., Kaminski-Hartenthaler, A., Noord, M. V., Forneris, C. A., Morgan, L. C., Gaynes, B. N., Wipplinger, J., Lux, L. J., Winkler, D., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011271.pub3 · Cited by 25
Review: The importance of early symptom relief in antidepressant treatment: focus on agomelatine
Lam, R. W. M. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810372979 · Cited by 20
Thomas, J., Khanam, R., & Vohora, D. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.06.008 · Cited by 18
Maniadakis, N., Kourlaba, G., Mougiakos, T., Chatzimanolis, I., & Jönsson, L. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-173 · Cited by 18
Molecular basis for the association between depression and circadian rhythm
Liu, I. Y., & Varinthra, P. (2019) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_181_18 · Cited by 21
Chen, Y., Li, J., Liao, M., He, Y., Dang, C., Yu, J., Xing, S., & Zeng, J. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000509 · Cited by 14
Young, A. H., Evitt, L., Brignone, M., Diamand, F., Atsou, K., Campbell, R., Cure, S., & Danchenko, N. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.019 · Cited by 15
Agomelatine: Its Role in the Management of Major Depressive Disorder
Cardinali, D. P., Vidal, M. F., & Vigo, D. E. (2012) · Clinical Medicine Insights Psychiatry · doi:10.4137/cmpsy.s7989 · Cited by 14
Laux, G., Barthel, B., Hajak, G., Lemke, M. R., & Volz, H. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0485-z · Cited by 13
Giannantonio, M. D., Montemitro, C., Sepede, G., Brunetti, M., Baroni, G., Corbo, M., Anders, M., Tavčar, R., Martinotti, G., & Manzoli, L. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001038 · Cited by 18
Yao, X.-W., Li, Y., Yu, Z.-J., Mo, C.-Y., Pan, H., & Li, C.-Y. (2021) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2021.106651 · Cited by 15
Иванов, С. В., & Samushiya, M. A. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s58994 · Cited by 14
Recognition and management of antidepressant discontinuation syndrome
Bhat, V., & Kennedy, S. H. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.170022 · Cited by 21
Recommandations pour switcher et arrêter les antidépresseurs
Gauthier, C., Abdel-Ahad, P., & Gaillard, R. (2018) · L Encéphale · doi:10.1016/j.encep.2018.08.001 · Cited by 15
Agomelatina: fallo hepático fulminante en paciente con hígado graso
Gruz, F., Raffa, S., Santucci, C., Papale, R. M., Videla, M. G., Fernández, M. G., Yantorno, S. E., & Descalzi, V. (2013) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2013.04.008 · Cited by 13
Antidepressant Discontinuation Syndrome
Kim, S. H., Kim, Y. S., & Kang, U. G. (2024) · 신경정신의학 · doi:10.4306/jknpa.2024.63.2.104 · Cited by 12
Déprimer par les nombres: Le façonnage statistique et psychométrique des dépressions contemporaines
Briffault, X., & Martin, O. (2012) · Sociologie et sociétés · doi:10.7202/1008239ar · Cited by 16
Aslan, E. A., Cerit, C., Talas, A., & Tural, Ü. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.4.351 · Cited by 12
Li, C., Xu, J., Zheng, Y., Chen, G., Wang, J., Ma, L., Qiao, Y., Niu, J., Wu, M., Zhang, H., et al. (2017) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c16-00866 · Cited by 11
Agomelatine: An Astounding Sui-generis Antidepressant?
Zhang, J., Zhou, Q.-G., Naveed, M., Li, L., Sheng, G., Du, Z., Zhou, Y., Sun, N., & Zhu, M.-Y. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666211209142546 · Cited by 11
Huang, J., Xie, X., Lyu, N., Fu, B., Zhao, Q., Zhang, L., & Wang, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1115008 · Cited by 14
Agomelatine: An Antidepressant Without Deterioration of Sexual Response
Sapetti, A. (2012) · Journal of Sex & Marital Therapy · doi:10.1080/0092623x.2011.613095 · Cited by 10
Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review
Moncrieff, J., Hobday, H., Sørensen, A., Read, J., Plöderl, M., Hengartner, M. P., Kamp, C. B., Jakobsen, J. C., Juul, S., Davies, J., et al. (2025) · Psychological Medicine · doi:10.1017/s0033291725100652 · Cited by 13
Guo, Y.-H., Zhou, L., Cui, Z.-A., Jian, W., Zhang, L., Xu, T., Xie, Y.-D., & Chen, H. (2023) · Medicine · doi:10.1097/md.0000000000035871 · Cited by 11
Circadian arrhythmia dysregulates emotional behaviors in aged Siberian hamsters
Prendergast, B. J., Onishi, K. G., Patel, P. N., & Stevenson, T. J. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.12.010 · Cited by 10
Sühs, K., Correll, C. U., Eberlein, C. K., Pul, R., Frieling, H., Bleich, S., & Kahl, K. G. (2015) · Brain and Behavior · doi:10.1002/brb3.318 · Cited by 9
Cohen, D., & Recalt, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320964097 · Cited by 15
Huang, C.-Y., Huang, M., Sun, M.-F., Lin, C., Wu, M., Lin, W.-C., & Yen, H. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s315572 · Cited by 9
Yu, Y., Gao, K., Yu, H., Shen, Y., & Li, H. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000878 · Cited by 11
Smyk, M. K., van Luijtelaar, G., Huysmans, H., & Drinkenburg, W. H. I. M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.062 · Cited by 8
Cerou, M., Peigné, S., Comets, E., & Chenel, M. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0379-x · Cited by 11
Zaccoletti, D., Mosconi, C., Gastaldon, C., Benedetti, L., Gottardi, C., Papola, D., Ponzi, O., Purgato, M., Naudet, F., Cristea, I. A., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00330-x · Cited by 13
Agomelatine: a review for general practitioners
Outhoff, K. (2012) · South African Family Practice · doi:10.1080/20786204.2012.10874212 · Cited by 9
Arıkan, M. K., İlhan, R., Pogarell, O. M., & Metin, B. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.024 · Cited by 6
Perugi, G., Quaranta, G., & Bucci, N. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1021918 · Cited by 6
Ov, V. (2013) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-013-9860-7 · Cited by 5
Berardis, D. D. (2011) · ChronoPhysiology and Therapy · doi:10.2147/cpt.s16972 · Cited by 4
Agomelatine as monotherapy for major depression: an outpatient, open-label study
Pečeňák, J., & Novotny, V. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s49062 · Cited by 5
Toward Early, Personalized, Rational Polypharmacy In Psychiatry: A Tri-Dimensional Approach
Niculescu, A. B., & Hulvershorn, L. A. (2010) · Psychopharm Review · doi:10.1097/01.idt.0000366925.86837.fe · Cited by 10
The Role of 5-HT2C Receptors in the Pathophysiology and Treatment of Depression
Dremencov, E., Folgering, J. H. A., Hogg, S., Tecott, L. H., & Cremers, T. I. F. H. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-941-3_12 · Cited by 4
Evidence-based pharmacotherapy of major depressive disorder
Dupuy, J. M., Ostacher, M. J., Huffman, J. C., Perlis, R. H., & Nierenberg, A. A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.005 · Cited by 4
Agomelatine: Protecting the CNS from the Effects of Stress
Maccari, S., & Nicoletti, F. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00174.x · Cited by 3
Pan, Z., Zhang, H., Li, B., Huang, Z., Hu, Y., Chen, J., Lam, R. W. M., & Fang, Y. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119460 · Cited by 3
Arango, C., Fegert, J. M., Picarel-Blanchot, F., Marx, U., Truffaut-Chalet, L., Pénélaud, P., Buitelaar, J. K., & the study investigators (2024) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-024-02587-4 · Cited by 3
Melatonin in Mood Disorders and Agomelatine’s Antidepressant Efficacy
Srinivasan, V., Lauterbach, E. C., Shillcutt, S. D., Berardis, D. D., Kuppuswamy, P. S., Zakaria, R., Othman, Z., Acuña-Castroviejo, D., & Partonen, T. (2013) · Springer eBooks · doi:10.1007/978-81-322-0825-9_20 · Cited by 3
Agomelatine in unipolar depression in clinical practice: a retrospective chart review
Langan, J., Shajahan, P. M., Martin, D. J., & Carleton, R. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311423296 · Cited by 2
Agomelatine, Melatonin and Depression
Norman, T. R. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_18 · Cited by 3
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.024 · Cited by 2
Agomelatine in Depressive Disorders
Kennedy, S. H., & Placenza, F. M. (2013) · Springer eBooks · doi:10.1007/978-81-322-0825-9_19 · Cited by 1
Agomelatin – Update aktueller Daten 2015
Volz, H. (2015) · Die Psychiatrie · doi:10.1055/s-0038-1669896 · Cited by 1
Пантелеева, Н. Г., Шурлыгина, А. В., & Труфакин, В. А. (2013) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-013-2282-2 · Cited by 1
Mitchell, P. B. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00002-7 · Cited by 1
Drugs to Treat Anxiety and Insomnia
Baldwin, D. S., & Huneke, N. T. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.010 · Cited by 1
Agomelatine: Profile and applications to depression
Norman, T. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00032-3 · Cited by 2
▼Agomelatine for major depressive episodes
(2010) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2010.08.0043 · Cited by 1
Diagnosis and treatment of depression according to the functional recovery paradigm
Михайлович, У. Г. (2023) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2023-5-79-86 · Cited by 1
Tyuvina, N. A., & Смирнова, В. Н. (2014) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-014-9895-4 · Cited by 1
Melatonergic Antidepressant Agomelatine and Its Efficacy in Depressive Disorders
Srinivasan, V., Berardis, D. D., Fornaro, M., Lopez-Munoz, F. J., Zakaria, R., Yaacob, M. J., & Othman, Z. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_17 · Cited by 1
Pharmacological Treatment of Generalized Anxiety Disorder (GAD)
Baldwin, D. S. (2020) · Wiley eBooks · doi:10.1002/9781119189909.ch14 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.083 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.018 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.032 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.017 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.086 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.046 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.055 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.071 · Cited by 1
Administrative criteria in the relapse of depressive disorder: a critical appraisal
Bernal-Cueto, S., Cegla-Schvartzman, F., & Baca-García, E. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1796386
Agomelatin: Yeni Antidepresan İlaç ve Yeni Bulgular
Akdeniz, F. (2012) · Journal of Mood Disorders · doi:10.5455/jmood.20120924064532 · Cited by 1
Considerations On The Effectiveness Of Valdoxan Therapy In Depressive And Anxiety Disorders
Boer, M., Udangiu, L. N., & Ţilea, L. (2013) · Management in Health · doi:10.5233/mih.v17i4.293
Future perspectives on the pharmacological management of depression
Yates, S., Smith, E., Alhaj, H. A., & McAllister-Williams, H. (2013) · Clinical Investigation · doi:10.4155/cli.12.152
Impact de l’utilisation de l’agomélatine sur la consommation d’hypnotiques
Compagnat, F., Chalmendrier, C., Méjat, E., Rebrab, R., Netillard, C., Martin, G., & Tissot, E. (2012) · Le Pharmacien Hospitalier et Clinicien · doi:10.1016/j.phclin.2012.09.005
Sup, W. Y., 왕희령, & Bahk, W. (2014) · 대한정신약물학회지
Potential novel treatments for bipolar depression
Zarate, C. A., & Manji, H. K. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8567-5_12 · Cited by 1
Agomelatine: A Novel Antidepressant Therapy
Commodore, M. M. (2012) · Psychopharm Review · doi:10.1097/01.psyphr.0000423006.73274.e7 · Cited by 1
Melatonergic Drugs as Therapeutic Agents for Insomnia and Depressive Disorders
Srinivasan, V., Gobbi, G., Shillcutt, S. D., & Suzen, S. (2014) · CRC Press eBooks · doi:10.1201/b17448-28
Antidépresseurs : aspects thérapeutiques
Souaiby, L., Gauthier, C., Poirier, M., Olié, J., Gaillard, R., & Krebs, M. (2016) · Time to knit · doi:10.1016/s0246-1072(16)75752-x
Light-At-Night and Mood: Examining The Role Of Sex In C57Bl/6 Mice
Cleary-Gaffney, M. (2015) · Maynooth University ePrints and eTheses Archive (Maynooth University)
Agomelatine as a Novel Pharmacotherapy of Anxiety Disorders
Min, J. A., & Chae, J. (2011) · 대한정신약물학회지
Melatonin receptor agonists/5-HT 2C antagonists
Kennedy, S. H., & Rizvi, S. J. (2012) · doi:10.2217/ebo.11.291
Kaufmann, M., & Lehmann, P. (2019) · NeuroTransmitter · doi:10.1007/s15016-019-6915-1
Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy
Brandt, L., Heinz, A., & Henssler, J. F. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_28-1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.009
Laux, G. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_31-1 · Cited by 1
Potential Novel Treatments in Bipolar Depression
Machado‐Vieira, R., Henter, I. D., Manji, H. K., & Zarate, C. A. (2016) · Milestones in drug therapy · doi:10.1007/978-3-319-31689-5_12
Laux, G. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_55
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.058
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.051
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.007
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.045 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.008
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.097
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.082
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.074
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.093
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.028
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.026
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.029
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.035
Metadata
- Authors
- Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group
- Affiliations
- Warneford Hospital (GB)
- Corresponding author
- Goodwin, Guy M.
- ORCID
- Goodwin, Guy M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-08-11
- Volume
- 70
- Issue
- 8
- Pages
- 1128-1137
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2059735897
- Semantic Scholar
- 1bd98c3c9aff0e1628639bd92c7138577e80d1c8
- Cited by
- 340
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 3 · 2021: 9 · 2020: 164 · 2019: 10 · 2018: 3 · 2017: 7 · 2016: 12 · 2015: 13 · 2014: 14 · 2013: 19 · 2012: 16
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- agomelatine, major depressive disorder, relapse prevention, continuation treatment, discontinuation syndrome, 5-HT2C receptor antagonism, antidepressant efficacy, placebo response, early recurrence
- MeSH terms
- Acetamides, Adolescent, Adult, Aged, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypnotics and Sedatives, Male, Melatonin, Middle Aged, Naphthalenes, Substance Withdrawal Syndrome, Treatment Outcome, Receptor, Melatonin, MT1, Receptor, Melatonin, MT2, Kaplan-Meier Estimate, Secondary Prevention, Serotonin 5-HT2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.